The once-a-day jab can provide insulin action for up to 42 hours, allowing diabetics to day-to-day dosing time when needed without raising the risk of hypoglycaemia. The injection will come in form of a prefilled pen and can enable a dosage of up to 80 units in a single use. The company said that it will be revealing the pricing for Tresiba at the time of its launch.
"Tresiba (insulin degludec)-- a new basal insulin for adult patients with type 1 and type 2 diabetes to be available in India as a new treatment option. We are through with clinical trials and have received the necessary approvals. We hope to launch it by the end of this year", Novo Nordisk India Managing Director Melvin D'souza said.